Boston Scientific Reports Positive Clinical Trial Results For Its Lotus Valve System

The REPRISE II Extended Cohort study was an extension of the REPRISE II clinical trial that reported strong performance data at one year in September 2014. On the other hand, the RESPOND Post-Market Study was initiated in June 2014 to assess the performance and clinical outcomes of its Lotus TAVR in the treatment of patients with severe calcific aortic stenosis. The primary measures of outcome included all-cause mortality rates at 30 days and 1 year after the implant procedure.